Media Articles Related to Ampyra (Dalfampridine)
Task length linked with cognitive fatigue in multiple sclerosis
Source: Multiple Sclerosis News From Medical News Today [2015.01.24]
Kessler Foundation researchers have authored a new article that provides insight into the factors that contribute to cognitive fatigue in individuals with multiple sclerosis (MS).
More Support for Stem Cell Therapy in Multiple Sclerosis
Source: Medscape NeurologyHeadlines [2015.01.21]
Nonmyeloablative hematopoietic stem cell transplantation can reduce disability and improve quality of life in relapsing-remitting MS, researchers find.
Medscape Medical News
Early Study Says Stem Cells May Reverse Multiple Sclerosis Disability
Source: MedicineNet Clinical Trials Specialty [2015.01.21]
Title: Early Study Says Stem Cells May Reverse Multiple Sclerosis Disability
Category: Health News
Created: 1/20/2015 12:00:00 AM
Last Editorial Review: 1/21/2015 12:00:00 AM
Ulcer Bacteria Tied to Lower Multiple Sclerosis Risk in Women
Source: MedicineNet Helicobacter Pylori Specialty [2015.01.20]
Title: Ulcer Bacteria Tied to Lower Multiple Sclerosis Risk in Women
Category: Health News
Created: 1/20/2015 12:00:00 AM
Last Editorial Review: 1/20/2015 12:00:00 AM
PLEGRIDY (peginterferon beta-1a) receives SMC approval for the treatment of relapsing remitting multiple sclerosis
Source: Multiple Sclerosis News From Medical News Today [2015.01.15]
PLEGRIDY® (peginterferon beta-1a) has been approved by the Scottish Medicines Consortium (SMC) as a treatment for adults with relapsing- remitting multiple sclerosis (RRMS).
Published Studies Related to Ampyra (Dalfampridine)
Dalfampridine extended release: in multiple sclerosis. [2010.10.01]
Dalfampridine extended release (ER) is an orally administered formulation of dalfampridine (fampridine, 4-aminopyridine), a potassium channel antagonist indicated for the improvement in walking ability in patients with multiple sclerosis (MS). Oral dalfampridine ER improved walking ability in patients with MS in three randomized, double-blind trials of up to 15 weeks' duration...
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. [2010.10]
OBJECTIVE: A previous phase 3 study showed significant improvement in walking ability in multiple sclerosis (MS) patients treated with oral, extended-release dalfampridine (4-aminopyridine) 10mg twice daily. The current study was designed to confirm efficacy and further define safety and pharmacodynamics... INTERPRETATION: This interventional study provides class 1 evidence that dalfampridine extended-release tablets produce clinically meaningful improvement in walking ability in a subset of people with MS, with the effect maintained between doses.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. 
to confirm efficacy and further define safety and pharmacodynamics... INTERPRETATION: This interventional study provides class 1 evidence that
Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. [2011.07]
BACKGROUND: Multiple sclerosis (MS) can cause progressive walking impairment that contributes to disability, loss of independence, and reduced quality of life. Dalfampridine (4-aminopyridine), a voltage-dependent potassium channel blocker, has been shown to improve walking in patients with MS, as demonstrated by an increase in walking speed. OBJECTIVE: To summarize knowledge about the mechanism of action of dalfampridine in the context of clinical evidence of walking improvement in MS patients... CONCLUSIONS: The extended-release formulation of dalfampridine has been shown in clinical trials to improve walking speed in approximately one third of MS patients with ambulatory impairment. The putative mechanism of action of dalfampridine is restoration of action potential conduction via blockade of an as yet uncharacterized subset of potassium channels in demyelinated axons.
Treatment of walking impairment in multiple sclerosis with dalfampridine. [2011.03]
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyridine (4-AP), is the potassium channel blocker that has been studied most extensively in MS and other demyelinating neurologic disorders...
Clinical Trials Related to Ampyra (Dalfampridine)
A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease [Recruiting]
The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in
Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in
multiple sclerosis. There are multiple studies to suggest that persons with multiple
sclerosis benefit from this medication and have major improvements in gait after taking this
medication. However, this medication was never studied in Parkinson's disease. This study
aims to learn about possible benefits of AMPYRA in Parkinson's disease (PD).
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis [Recruiting]
The purpose of this study is to investigate the safety and efficacy of a lower dose of
dalfampridine extended release tablets compared to the currently approved dose in improving
walking in Multiple Sclerosis patients.
Safety and Efficacy of Dalfampridine in Patients With Cerebral Palsy [Recruiting]
A double-blind, placebo-controlled, crossover study in patients with cerebral palsy (CP) to
evaluate the effect of a single dose of dalfampridine extended release (ER) tablets on
Ampyra for Optic Neuritis in MS [Recruiting]
Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and
blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the
hypothesis that dalfampridine, when administered to subjects with incomplete visual recovery
after optic neuritis from MS, will result in symptomatic improvement in visual function. The
study will consist of one screening/baseline visit, one visit during treatment with active
drug, and one visit on placebo. After the baseline visit, subjects will be randomly assigned
to receive study medication or placebo for the first three weeks, followed by a two week
wash-out, and then treatment reallocation for the latter three weeks.
Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury [Recruiting]
The purpose of this study is to determine the efficacy, safety, and tolerability of
treatment with dalfampridine in combination with locomotor training in persons with chronic,
motor incomplete SCI.
Reports of Suspected Ampyra (Dalfampridine) Side Effects
Gait Disturbance (64),
Urinary Tract Infection (63),
Inappropriate Schedule of Drug Administration (57),
Multiple Sclerosis Relapse (52),
Nausea (37), more >>